Frankfurt
04.02.26 | 08:19
0,459 Euro
-3,07 % -0,015
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:30 | Egetis Therapeutics AB: FDA's rare pediatric disease priority review program extended until 2029 | 62 | GlobeNewswire (Europe) | Stockholm, Sweden, February 4, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today noted that the U.S. Food and Drug Administration's (FDA's) Rare Pediatric... ► Artikel lesen | |
| Do | Egetis Therapeutics AB: Egetis Completes the U.S. Rolling NDA Submission for Emcitate (tiratricol) for Treatment of MCT8 Deficiency | 47 | GlobeNewswire (Europe) | Priority Review and Rare Pediatric Disease Priority Review Voucher requestedAnticipated regulatory decision in September 2026Emcitate® (tiratricol) U.S. launch expected in Q4 2026, if approvedStockholm... ► Artikel lesen | |
| 19.12.25 | Egetis Therapeutics AB: Egetis Therapeutics initiates New Drug Application in the USA for Emcitate (tiratricol) for MCT8 deficiency | 202 | GlobeNewswire (Europe) | Stockholm, Sweden, December 19, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the Company has initiated a rolling New Drug Application... ► Artikel lesen | |
| 10.12.25 | Egetis Therapeutics AB: Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate Across Central, Eastern, and Southeastern Europe | 117 | GlobeNewswire (Europe) | Stockholm, Sweden, December 10, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the Company, through its wholly-owned subsidiary Rare Thyroid... ► Artikel lesen | |
| 25.11.25 | Egetis-Aktie unter Druck: Positive Studiendaten können Kursverlust nach Q3-Zahlen nicht verhindern | 4 | Investing.com Deutsch | ||
| 25.11.25 | Egetis Therapeutics AB: Interim report Q3 2025 | 136 | GlobeNewswire (Europe) | Egetis to commence a rolling NDA submission in December as granted by the FDA for Emcitate® (tiratricol)· Egetis received FDA Breakthrough Therapy Designation for Emcitate® (tiratricol) for... ► Artikel lesen | |
| 14.11.25 | Egetis Therapeutics AB: Egetis announces positive results from the ReTRIACt study of Emcitate (tiratricol) in MCT8 deficiency | 117 | GlobeNewswire (Europe) | Positive topline results demonstrate a statistically significant (p=0.034) difference in the rate of change in serum T3 in patients randomized to withdrawal (placebo) vs. in patients continuing therapy... ► Artikel lesen | |
| EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.10.25 | Egetis Therapeutics AB: Egetis granted a rolling NDA review by FDA for Emcitate (tiratricol) based on currently available clinical data | 196 | GlobeNewswire (Europe) | The outcomes of a successful pre-NDA meeting with the FDA are:
As agreed with the FDA, the rolling NDA submission will commence in December 2025, targeting a complete NDA submission in early 2026 and... ► Artikel lesen | |
| 02.10.25 | Egetis Therapeutics AB: Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares | 169 | GlobeNewswire (Europe) | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA... ► Artikel lesen | |
| 21.08.25 | Egetis Therapeutics: Aktie steigt nach Q2-Zahlen trotz verfehlter Umsatzprognose | 2 | Investing.com Deutsch | ||
| 21.08.25 | Egetis Therapeutics AB: Interim report Q2 2025 | 224 | GlobeNewswire (Europe) | Egetis reports progress towards US NDA submission for tiratricol· FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis... ► Artikel lesen | |
| 18.08.25 | Egetis Therapeutics AB: Egetis reports progress towards US NDA submission for tiratricol | 504 | GlobeNewswire (Europe) | FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis of the survival data set from the international real-world cohort study by... ► Artikel lesen | |
| 15.07.25 | Egetis Therapeutics AB: Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency | 325 | GlobeNewswire (Europe) | Stockholm, Sweden, July 15, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough... ► Artikel lesen | |
| 05.05.25 | Egetis Therapeutics AB: Egetis Confirms Launch of Emcitate in Germany | 491 | GlobeNewswire (Europe) | For investors and media only
Stockholm, Sweden, May 5, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), a pharmaceutical company dedicated to developing therapies... ► Artikel lesen | |
| 30.04.25 | Egetis Therapeutics AB: Interim report Q1 2025 | 205 | GlobeNewswire (Europe) | Egetis plans to launch Emcitate® in the first country, Germany, on May 1, 2025The European Commission approved Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency.In... ► Artikel lesen | |
| 26.02.25 | Egetis Therapeutics AB: Year-End Report January-December 2024 | 377 | GlobeNewswire (Europe) | European Commission has approved Egetis' Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency· Egetis expects to launch Emcitate in the first country, Germany... ► Artikel lesen | |
| 13.02.25 | Egetis Therapeutics AB: European Commission approves Egetis' Emcitate (tiratricol) as the first and only treatment for patients with MCT8 deficiency | 470 | GlobeNewswire (Europe) | Stockholm, Sweden, February 13, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol)... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANOFI | 81,25 | +0,77 % | Aktien Europa: Anleger warten auf Fed - Technologiewerte stark, Luxus schwach | PARIS/LONDON/ZÜRICH (dpa-AFX) - Vor der Bekanntgabe der Zinsentscheidung der US-Notenbank Fed sowie der Veröffentlichung von Geschäftszahlen von Microsoft und Tesla am Abend haben sich die Marktteilnehmer... ► Artikel lesen | |
| GSK | 24,210 | +7,41 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK mit einem Kursziel von 2100 Pence auf "Buy" belassen. Die Briten hätten im vierten Quartal 2025 bei Umsatz und Ergebnis... ► Artikel lesen | |
| ASTRAZENECA | 159,75 | -0,41 % | BERENBERG stuft ASTRAZENECA auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Astrazeneca von 145 auf 160 Pence angehoben und die Einstufung auf "Buy" belassen. Zur Jahresmitte dürften Studienergebnisse... ► Artikel lesen | |
| TILRAY BRANDS | 6,350 | -3,50 % | Tilray Brands, Inc.: Tilray's CC Pharma Recognized as a TOP 100 Innovator in Germany | Award Recognizes CC Pharma as an Innovative Leader and Trusted Partner in the European Pharmaceutical MarketDENSBORN, Germany, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division... ► Artikel lesen | |
| DERMAPHARM | 35,100 | +1,15 % | Kissigs Nebenwerte-Analyse zu Dermapharm: Küssen Insiderkäufe jetzt auch den Kurs wieder wach? | Im Magazin "Der Nebenwerte Investor" von Traderfox finden sich regelmäßig Analysen von mir zu deutschen Nebenwerten. Das Magazin ist kostenpflichtig und wer dieses oder eine der weiteren Börsenzeitschriften... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 3,580 | +5,29 % | Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) | TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 13,800 | -4,83 % | Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report | ||
| CASSAVA SCIENCES | 1,644 | -1,62 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| OPKO HEALTH | 1,055 | -0,73 % | OPKO Health, Inc.: OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism | This is the third program that successfully combines Entera's oral peptide N-Tab- platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,285 | -6,41 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| SOLIGENIX | 1,160 | 0,00 % | SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Study results support advancing SGX945 in this difficult-to-treat orphan disease
Results suggest potential durability of response for maintenance therapy
PRINCETON, N.J., Dec. 18... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,039 | 0,00 % | BetterLife Pharma Inc.: BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco | Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,178 | -2,36 % | Theriva Biologics, Inc.: Theriva Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 | - Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,960 | -29,93 % | NovaBay Pharmaceuticals, Inc. - 8-K, Current Report | ||
| BAYER | 45,150 | -0,27 % | Bayer-Aktie: Warum Anleger wieder mutig zugreifen | Die Bayer-Aktie ist zurück auf dem Radar der Investoren - und diesmal mit Nachdruck. Binnen sechs Monaten hat der Titel um mehr als +60% auf aktuell 46,74 € zugelegt und befindet sich seit November... ► Artikel lesen |
Das Unternehmen EGETIS THERAPEUTICS AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,07 % bei einem Aktienkurs von 0,459 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EGETIS THERAPEUTICS AB finden Sie auf Wallstreet Online.